CXCL9 and melanoma: Similar to results observed in patients with advanced melanoma from RELATIVITY-047 (ref. 10), pharmacodynamic and target engagement evaluation in patients in RELATIVITY-098 demonstrated that inflammatory cytokines (interferon gamma (IFNγ), C-X-C motif chemokine ligand 9 and C-X-C motif chemokine ligand 10 (CXCL9 and CXCL10)) were significantly increased by nivolumab plus relatlimab and nivolumab treatment, with greater increases in the nivolumab plus relatlimab arm than in the nivolumab arm (Fig. 3a).